Abstract: The present invention relates to a process for the preparation of alkyl esters of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid, which are intermediates useful in the synthesis of (S)-N-(1-cyanocyclopropyl)-5-cyclopropyl-4,4-difluoro-2-(S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethylamino)pentanamide and related compounds, which are compounds that are cysteine protease inhibitors.
Type:
Application
Filed:
August 16, 2010
Publication date:
February 24, 2011
Applicant:
ViroBay, Inc.
Inventors:
Barry Hart, Jeff Dener, Michael Green, Michael Standen, Oldrich Kocian
Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Type:
Grant
Filed:
April 1, 2008
Date of Patent:
February 22, 2011
Assignee:
Virobay, Inc.
Inventors:
John O. Link, Craig J. Mossman, Jie Liu, Soon Hyung Woo
Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Type:
Application
Filed:
February 23, 2010
Publication date:
December 2, 2010
Applicant:
ViroBay, Inc.
Inventors:
Michael Graupe, John O. Link, Michael G. Roepel
Abstract: The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Type:
Application
Filed:
October 23, 2009
Publication date:
October 21, 2010
Applicant:
ViroBay, Inc.
Inventors:
Michael Graupe, John O. Link, Chandrasekar Venkataramani
Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Type:
Grant
Filed:
October 3, 2007
Date of Patent:
August 24, 2010
Assignee:
ViroBay, Inc.
Inventors:
John O. Link, Craig J. Mossman, Jie Liu, Soon Hyung Woo
Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Type:
Grant
Filed:
December 17, 2008
Date of Patent:
April 13, 2010
Assignee:
ViroBay, Inc.
Inventors:
Michael Graupe, John O. Link, Michael G. Roepel
Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Abstract: The present invention relates to a process for the preparation of (2S,3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamides as well as novel compounds prepared or used in the process.
Abstract: The present invention is directed to compounds that have the dual property of acting as cathepsin S inhibitors and of inhibiting HCV replication. Such compounds are therefore useful in treating disease states that include hepatitis C, Alzheimer's disease, and autoimmune disorders. The present invention is also directed to pharmaceutical compositions containing these compounds, and processes for preparing the compounds.
Type:
Application
Filed:
October 22, 2008
Publication date:
October 29, 2009
Applicant:
ViroBay, Inc.
Inventors:
Leslie Jean Holsinger, Kyle Elrod, John O. Link, Michael Graupe, In Jong Kim
Abstract: The present invention is directed to compounds that are antiviral agents. Specifically the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Type:
Grant
Filed:
June 28, 2006
Date of Patent:
October 27, 2009
Assignee:
ViroBay, Inc.
Inventors:
Michael Graupe, John O. Link, Chandrasekar Venkataramani
Abstract: The present invention is directed to compounds of formula (I) that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them. Wherein R3 is -alkylene-SO2NR5R6.
Type:
Application
Filed:
December 1, 2005
Publication date:
September 17, 2009
Applicant:
Virobay, Inc.
Inventors:
Soon H. Woo, Randall W. Vivian, John O. Link
Abstract: The present invention relates to a process for the preparation of (2S,3S)-3-amino-N-cyclopropyl-2-hydroxyalkanamides, and their use in the preparation of HCV inhibitors and cathepsin inhibitors.
Abstract: The present invention is directed to a method of using compounds of Formula (I) to inhibit Cathepsin B. Specifically the compounds of the present invention are useful as therapeutic agents for the treatment of tumor invasion, metastasis, Alzheimer's Disease, arthritis, inflammatory diseases such as chronic and acute pancreatitis, inflammatory airway disease, and bone and joint disorders, including osteoporosis, osteoarthritis, rheumatoid arthritis, psoriasis, and other autoimmune disorders, liver fibrosis, including liver fibrosis associated with HCV, all types of steatosis (including non-alcoholic steatohepatitis) and alcohol-associated steatohepatitis, non-alcoholic fatty liver disease, forms of pulmonary fibrosis including idiopathic pulmonary fibrosis, pathological diagnosis of interstitial pneumonia following lung biopsy, renal fibrosis, cardiac fibrosis, retinal angiogenesis and fibrosis/gliosis in the eye, schleroderma, and systemic sclerosis.
Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Type:
Application
Filed:
December 17, 2008
Publication date:
July 2, 2009
Applicant:
Virobay, Inc.
Inventors:
Michael Graupe, John O. Link, Michael G. Roepel
Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Type:
Grant
Filed:
September 17, 2004
Date of Patent:
June 16, 2009
Assignee:
Virobay, Inc.
Inventors:
John O. Link, Craig J. Mossman, Soon H. Woo, Sheila M. Zipfel
Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Type:
Grant
Filed:
March 17, 2006
Date of Patent:
February 10, 2009
Assignee:
Virobay, Inc.
Inventors:
Michael Graupe, John O. Link, Michael G. Roepel
Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S, and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.
Type:
Application
Filed:
April 1, 2008
Publication date:
November 27, 2008
Applicant:
ViroBay, Inc.
Inventors:
John O. Link, Craig J. Mossman, Jie Liu